Day: May 14, 2025

Poster presentations across all programs, including data from HELIOS long-term extension trial of bitopertin in erythropoietic protoporphyria (EPP), additional durability data from Phase 1b study of DISC-0974 in anemia of myelofibrosis (MF), and additional data from DISC-3405 studies in healthy volunteers Management will host a corporate update conference call on Monday June 16 at 8:00 am ET / 2:00 pm CESTWATERTOWN, Mass., May 14, 2025 (GLOBE NEWSWIRE) — Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced that it will present data from multiple programs in its hematology portfolio at the upcoming European Hematology Association (EHA) 2025 Congress,...

Salt Lake City, Utah, May 14, 2025 (GLOBE NEWSWIRE) — Co-Diagnostics, Inc. (Nasdaq: CODX) (the “Company” or “Co-Dx”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that they will be participating in the D. Boral Capital (“DBC”) Inaugural Global Conference on May 14, 2025 in New York City. The DBC conference connects emerging growth issuers across multiple sectors with institutional investors. Company representatives will be participating in one-on-one meetings to introduce institutions to the Company’s value proposition and to the upcoming Co-Dx PCR* testing platform. More information about the conference can be found here. *The Co-Dx PCR platform (including the PCR Home™, PCR Pro™, mobile app, and all associated tests) is subject...

LONDON, May 14, 2025 (GLOBE NEWSWIRE) — Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces the online publication of three abstracts submitted to the European Hematology Association (EHA) Congress, to be held June 12-15, 2025, Milan, Italy. Autolus will have two oral and one poster presentation, which includes updated follow up from the FELIX study of obecabtagene autoleucel (obe-cel) in adult patients with relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL). Oral S113: Title: Can CAR T-cell therapy be a definitive treatment for adult r/r B-ALL without transplant? Long-term findings and predictors of sustained remission for obecabtagene autoleucelSession Name: s447 Immunotherapy...

– Revumenib abstracts highlight compelling results in acute leukemia across the frontline and R/R setting and multiple genetic populations, including mNPM1, KMT2Ar, and NUP98r – – Axatilimab abstracts highlight the robust responses observed in different organs and subgroups of patients with chronic GVHD in the AGAVE-201 trial – NEW YORK, May 14, 2025 (GLOBE NEWSWIRE) — Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that multiple abstracts showcasing clinical data for Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) were accepted for presentation at the 30th European Hematology Association (EHA) Annual Congress Meeting being held June 12-15, 2025, in Milan, Italy. “The data being presented at EHA showcase the potential for revumenib...

Presentation to Include Updated Data from 17 Sickle Cell Disease Patients in the Ongoing BEACON Phase 1/2 Clinical Trial Evaluating Safety and Efficacy of BEAM-101 Beam to Host Investor Webcast on Friday, June 13, 2025, at 4:00 p.m. ET CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) — Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will present new data from the BEACON Phase 1/2 clinical trial of BEAM-101 in sickle cell disease (SCD) at the European Hematology Association 2025 Congress (EHA2025), taking place June 12-15, 2025, in Milan, Italy. BEAM-101 is an investigational genetically modified ex vivo cell therapy for the treatment SCD with severe vaso-occlusive crises (VOCs). “We are excited to share an updated safety...

SINGAPORE, May 14, 2025 (GLOBE NEWSWIRE) — Primech Holdings Limited (“Primech” or the “Company”) (Nasdaq: PMEC), an established technology-driven facility services provider in the public and private sectors operating mainly in Singapore, today announced that it has received notice from the Nasdaq Stock Market (“Nasdaq”) on May 13, 2025 informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the “Rule”) for continued listing on The Nasdaq Capital Market.  Primech was previously notified by Nasdaq on May 14, 2024 that it was not in compliance with the minimum bid price rule because its ordinary share failed to meet the closing bid price of $1.00 or more for 30 consecutive business days. In order to regain compliance...

Preclinical data highlight improved potency vs. asciminib across multiple clinically relevant variants of BCR-ABL including difficult-to-treat resistance mutations Early dose-escalation data from Phase 1 CARDINAL study of TERN-701 in CML patients showed compelling molecular responses in patients with heavily pre-treated CML, including deepening responses in patients with poor response to asciminib Additional safety and efficacy data from CARDINAL, including 6-month major molecular response (MMR) rates expected 4Q 2025 FOSTER CITY, Calif., May 14, 2025 (GLOBE NEWSWIRE) — Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that preclinical...

Preclinical studies achieved therapeutically relevant gene editing levels of the HBG1/2 promoter & favorable biodistribution profile in non-human primates using a clinically validated editing strategy Data reinforces continued development as a potentially transformative, in vivo approach to treating sickle cell disease and beta thalassemia CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company, today announced that new data from a study in non-human primates (NHPs) has been accepted for a poster presentation at the European Hematology Association (EHA) 2025 Congress being held June 12-15, 2025, in Milan, Italy. Key delivery, editing, and biodistribution data from an ongoing study in NHPs will be shared, including:High efficiency HSC delivery of editing cargo. Therapeutically...

LODI, Calif., May 14, 2025 (GLOBE NEWSWIRE) — Farmers & Merchants Bancorp (OTCQX: FMCB) (the “Company” or “FMCB”), the parent company of Farmers & Merchants Bank of Central California (the “Bank” or “F&M Bank”), the Board of Directors declared a mid-year cash dividend of $9.30 per share, an increase of 5.7% over the $8.80 per share paid in July of 2024. The cash dividend is payable on July 1, 2025, to shareholders of record on June 10, 2025. Net income over the trailing twelve months was $88.7 million compared with $87.5 million for the same trailing period a year earlier. Diluted earnings per share over the trailing twelve months totaled $123.32, up 5.97% compared with $116.37 for the same trailing period a year ago. For the quarter ended March 31, 2025, Farmers & Merchants Bancorp reported net income of $23.0...

Vancouver, British Columbia and West Palm Beach, FL, May 14, 2025 (GLOBE NEWSWIRE) — AgriForce Growing Systems Ltd. (“AgriForce” or the “Company”) (NASDAQ: AGRI), a diversified technology and infrastructure company focused on digital energy innovation, is pleased to announce the successful delivery of its previously announced order of 500 Bitmain S19j Pro 100T Bitcoin mining machines to its EPCM contractor for installation at the Company’s second OH facility in East Palestine, Ohio. Once installation is complete, the delivered equipment is expected to add an additional 50 petahash per second (PH/s) of new mining capacity, increasing AgriForce’s total operational Ohio hashrate to 130 PH/s. This includes the Company’s existing 80 PH/s running at its 3 MW facility in Westpoint, Ohio. Installation is now expected to occur on or about...